(NASDAQ: GNFT) Genfit Sa's forecast annual revenue growth rate of 2.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.15%.
Genfit Sa's revenue in 2025 is $53,423,529.On average, 9 Wall Street analysts forecast GNFT's revenue for 2025 to be $3,645,836,657, with the lowest GNFT revenue forecast at $490,025,088, and the highest GNFT revenue forecast at $9,098,965,843. On average, 9 Wall Street analysts forecast GNFT's revenue for 2026 to be $2,422,624,032, with the lowest GNFT revenue forecast at $980,050,176, and the highest GNFT revenue forecast at $3,958,702,675.
In 2027, GNFT is forecast to generate $2,912,249,100 in revenue, with the lowest revenue forecast at $1,749,389,564 and the highest revenue forecast at $4,068,958,320.